Revenue Beat: Entero Healthcare Solutions Limited Exceeded Revenue Forecasts By 5.6% And Analysts Are Updating Their Estimates
Shareholders of Entero Healthcare Solutions Limited (NSE:ENTERO) will be pleased this week, given that the stock price is up 16% to ₹1,427 following its latest first-quarter results. Results overall were respectable, with statutory earnings of ₹26.40 per share roughly in line with what the analysts had forecast. Revenues of ₹19b came in 5.6% ahead of analyst predictions. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Entero Healthcare Solutions after the latest results.
Following the latest results, Entero Healthcare Solutions' four analysts are now forecasting revenues of ₹82.3b in 2027. This would be a notable 15% improvement in revenue compared to the last 12 months. Per-share earnings are expected to bounce 34% to ₹38.70. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹81.4b and earnings per share (EPS) of ₹37.76 in 2027. So the consensus seems to have become somewhat more optimistic on Entero Healthcare Solutions' earnings potential following these results.
See our latest analysis for Entero Healthcare Solutions
The consensus price target rose 6.4% to ₹1,614, suggesting that higher earnings estimates flow through to the stock's valuation as well. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Entero Healthcare Solutions, with the most bullish analyst valuing it at ₹1,800 and the most bearish at ₹1,500 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 21% growth on an annualised basis. That is in line with its 24% annual growth over the past three years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 18% annually. It's clear that while Entero Healthcare Solutions' revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Entero Healthcare Solutions' earnings potential next year. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Entero Healthcare Solutions going out to 2029, and you can see them free on our platform here..
It might also be worth considering whether Entero Healthcare Solutions' debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.